Ross Osborn
Stock Analyst at Cantor Fitzgerald
(3.37)
# 1,000
Out of 4,761 analysts
100
Total ratings
45.98%
Success rate
4.67%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMTI Sanara MedTech | Reiterates: Overweight | $44 | $33.69 | +30.60% | 5 | Jan 23, 2025 | |
| PRE Prenetics Global | Reiterates: Overweight | $9 | $5.33 | +68.86% | 7 | Jan 16, 2025 | |
| XGN Exagen | Reiterates: Overweight | $8 | $3.58 | +123.46% | 5 | Jan 13, 2025 | |
| AVR Anteris Technologies Global | Initiates: Overweight | $9 | $8.25 | +9.09% | 1 | Jan 7, 2025 | |
| RCEL AVITA Medical | Reiterates: Overweight | $21 | $9.75 | +115.38% | 10 | Dec 24, 2024 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $11 → $12 | $6.30 | +90.48% | 10 | Dec 6, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Overweight | $3 → $2 | $1.46 | +36.99% | 4 | Nov 15, 2024 | |
| ELUT Elutia | Reiterates: Overweight | $10 | $3.22 | +210.56% | 9 | Nov 15, 2024 | |
| NYXH Nyxoah | Reiterates: Overweight | $16 | $10.35 | +54.63% | 4 | Nov 5, 2024 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $14 | $13.85 | +1.08% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $99.54 | -3.56% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $13.77 | +30.72% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.54 | +127.27% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $7.98 | +37.84% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.55 | +352.49% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.65 | +142.42% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $5.74 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.3 | $0.22 | +1,400.00% | 5 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.21 | +55.76% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 | $17.84 | +40.13% | 7 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $12 | $18.00 | -33.33% | 2 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.79 | +987.40% | 2 | Aug 18, 2023 |
Sanara MedTech
Jan 23, 2025
Reiterates: Overweight
Price Target: $44
Current: $33.69
Upside: +30.60%
Prenetics Global
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $5.33
Upside: +68.86%
Exagen
Jan 13, 2025
Reiterates: Overweight
Price Target: $8
Current: $3.58
Upside: +123.46%
Anteris Technologies Global
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $8.25
Upside: +9.09%
AVITA Medical
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $9.75
Upside: +115.38%
Nano-X Imaging
Dec 6, 2024
Maintains: Overweight
Price Target: $11 → $12
Current: $6.30
Upside: +90.48%
Lucid Diagnostics
Nov 15, 2024
Maintains: Overweight
Price Target: $3 → $2
Current: $1.46
Upside: +36.99%
Elutia
Nov 15, 2024
Reiterates: Overweight
Price Target: $10
Current: $3.22
Upside: +210.56%
Nyxoah
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $10.35
Upside: +54.63%
CVRx, Inc.
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $13.85
Upside: +1.08%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $99.54
Upside: -3.56%
Aug 14, 2024
Reiterates: Overweight
Price Target: $18
Current: $13.77
Upside: +30.72%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.54
Upside: +127.27%
Aug 1, 2024
Reiterates: Overweight
Price Target: $11
Current: $7.98
Upside: +37.84%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.55
Upside: +352.49%
May 3, 2024
Maintains: Overweight
Price Target: $3 → $4
Current: $1.65
Upside: +142.42%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.74
Upside: -
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $0.22
Upside: +1,400.00%
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.21
Upside: +55.76%
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $17.84
Upside: +40.13%
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $18.00
Upside: -33.33%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.79
Upside: +987.40%